ライフサイエンスコーパス: bone metastases

1 ium-223 ((223)Ra; for men with predominantly bone metastases).

2 genomes and new tumor biological properties (bone metastases).

3 e) or cancer (RAGE/leukocyte proteinase-3 in bone metastases).

4 stases (lymph nodes < 3 cm and five or fewer bone metastases).

5 n manipulating the tumor microenvironment in bone metastases.

6 s and lymph nodes and shows several PET-avid bone metastases.

7 attenuated cancer immune surveillance and/or bone metastases.

8 aging of the skeleton in patients at risk of bone metastases.

9 ing new approaches to therapeutically target bone metastases.

10 or SD208 effectively reduces prostate cancer bone metastases.

11 ression to determine the presence of growing bone metastases.

12 oved muscle function in mice with MDA-MB-231 bone metastases.

13 irculating tumour cells to colonize and form bone metastases.

14 ent to promote the growth of prostate cancer bone metastases.

15 s that are responsible for the initiation of bone metastases.

16 preventing skeletal-related events caused by bone metastases.

17 ration-resistant prostate cancer (mCRPC) and bone metastases.

18 luated CT, FDG PET, and FDHT PET features of bone metastases.

19 dicine to patients with prostate cancer with bone metastases.

20 on-resistant prostate cancer and symptomatic bone metastases.

21 on-resistant prostate cancer and symptomatic bone metastases.

22 n and response to treatment in patients with bone metastases.

23 recently approved in patients with CRPC with bone metastases.

24 ile bone microenvironment that might promote bone metastases.

25 e bone or planned orthopaedic surgery due to bone metastases.

26 d bisphosphonate and anti-RANKL therapies on bone metastases.

27 ith castration-resistant prostate cancer and bone metastases.

28 tate cancers and 87%-100% of prostate cancer bone metastases.

29 th castration-resistant prostate cancer with bone metastases.

30 d 2 drug candidates for the brain, lung, and bone metastases.

31 diagnostic and therapeutic implications for bone metastases.

32 ith castration-resistant prostate cancer and bone metastases.

33 s, including osteoporosis and cancer related bone metastases.

34 inaugurate innovative approaches to inhibit bone metastases.

35 bone that is coexpressed with cathepsin B in bone metastases.

36 onses similar to those observed in human PCa bone metastases.

37 ing therapeutic target for solid cancers and bone metastases.

38 est that osteoclast inhibition might prevent bone metastases.

39 tive in reducing the progression of melanoma bone metastases.

40 t with persistent androgen signaling in CRPC bone metastases.

41 in the progression of the disease, including bone metastases.

42 ng dissemination and plays a central role in bone metastases.

43 ntion of skeletal related events in men with bone metastases.

44 ncer patients have an extremely high rate of bone metastases.

45 PCa-133, were generated from prostate cancer bone metastases.

46 f the osteoblastic component of PCa skeletal bone metastases.

47 potential treatment option for patients with bone metastases.

48 s (SREs) in patients with breast cancer with bone metastases.

49 ly translate to more effective treatment for bone metastases.

50 ination, resulting in clinically significant bone metastases.

51 benefit for the treatment of lytic breast-to-bone metastases.

52 ith a neutralizing antibody reduced lung and bone metastases.

53 one-resorbing osteoclasts in human breast-to-bone metastases.

54 gies are commonly used to treat osteoblastic bone metastases.

55 osclerotic (i.e., excessive bone production) bone metastases.

56 predictor of RD in patients with MBC who had bone metastases.

57 egative NaF PET/CT and bone scintigraphy for bone metastases.

58 ith castration-resistant prostate cancer and bone metastases.

59 cits a sub-optimal response among those with bone metastases.

60 might hamper the visualization of small PCa bone metastases.

61 marrow from colorectal cancer patients with bone metastases.

62 ials of BMAs in control of pain secondary to bone metastases.

63 toring treatment response in prostate cancer bone metastases.

64 tal-related events and pain in patients with bone metastases.

65 and is associated with formation of prostate bone metastases.

66 for local tumor, lymph node metastases, and bone metastases.

67 ion in metastatic prostate cancer, including bone metastases.

68 , and (18)F-NaF PET/MRI for the detection of bone metastases.

69 h a single 8-Gy radiotherapy dose for 1 or 2 bone metastases.

70 g radiotracer for quantitative assessment of bone metastases.

71 the detection of otherwise occult nodal and bone metastases.

72 For the detection of bone metastases, (11)C- or (18)F-choline PET/CT has had

73 pulation with a relatively low prevalence of bone metastases (14%) is likely limited.

74 Our study included 53 RCC patients (19 with bone metastases, 25 with visceral metastases and 9 with

75 ical recurrences, 66 secondary treatments, 3 bone metastases, 3 prostate cancer deaths) during 2,750

76 s follows: nodal metastases, 6.1 versus 3.1; bone metastases, 8.8 versus 3.4; and visceral metastases

77 In those patients identified as having bone metastases according to the reference standard, SPE

78 important to detect and monitor response in bone metastases accurately.

79 The presence of bone metastases affects a patient's prognosis, quality o

80 t was present in human breast carcinomas and bone metastases after chemotherapy.

81 umans with breast- or lung cancer-associated bone metastases also had oxidized skeletal muscle RyR1 t

82 t the establishment and subsequent growth of bone metastases, although brain metastases were subject

83 idered suggestive for the detection of early bone metastases, although further validation is needed.

84 ograft (PDX) models from patient-derived HTR bone metastases and analyzed tumor cells, stroma, and mi

85 at is as good or better for the detection of bone metastases and better for the detection of lymph no

86 AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN.

87 beta may prevent the development of melanoma bone metastases and decrease the progression of establis

88 isphosphonates are used for the treatment of bone metastases and have been associated with a lower ri

89 apeutic agents to limit tumor cell growth in bone metastases and in other microenvironments in which

90 helial carcinoma with measurable disease and bone metastases and is generally well tolerated.

91 n of PSMA in prostate carcinoma cells and in bone metastases and lymph nodes related to the disease.

92 Associations of changes in volume of bone metastases and median apparent diffusion coefficien

93 he potential to effectively image osteolytic bone metastases and monitor the physiologic changes in t

94 Although treatment of bone metastases and myeloma bone disease is rarely curat

95 standing of the molecular events involved in bone metastases and new therapeutic avenues for an incur

96 n-resistant prostate cancer with two or more bone metastases and no known visceral metastases, who we

97 prostate cancer (CRPC) who have symptomatic bone metastases and no known visceral metastases.

98 e accurately and independently estimated for bone metastases and normal vertebrae.

99 he pathogenesis and clinical presentation of bone metastases and provide an update on existing and fu

100 one significantly increased the detection of bone metastases and reduced the time for interpretation.

101 aberrantly activated in both primary PCa and bone metastases and regulate distinct and overlapping fu

102 e, but little is known about prostate cancer bone metastases and TGF-beta.

103 4)Cu-RGD) as an imaging agent for osteolytic bone metastases and their associated inflammation by tar

104 The described improvements in the imaging of bone metastases and their response to therapy have led t

105 lation of parameters to biologic features of bone metastases and to response to therapy.

106 f radium-223 dichloride for the treatment of bone metastases and with the ongoing clinical developmen

107 ledronic acid does reduce the development of bone metastases and, for women with established menopaus

108 sponse in the primary tumor, soft tissue and bone metastases, and bone marrow.

109 cale (no bone metastases [M0], equivocal for bone metastases, and bone metastases present [M1]) and o

110 ratio, on cancer type, age, sex, presence of bone metastases, and SEER geographic region.

111 es associated with cancer aggressiveness and bone metastases, and the most upregulated gene was PMEPA

112 ith castration-resistant prostate cancer and bone metastases, and was associated with an increased fr

113 Bone metastases are a frequent cause of morbidity in can

114 Bone metastases are a major cause of morbidity and morta

115 Bone metastases are a major cause of morbidity in metast

116 Bone metastases are common in patients with advanced bre

117 Bone metastases are common, especially in more prevalent

118 astasis in prostate cancer and patients with bone metastases are deemed incurable.

119 Bone metastases are frequently the only source for obtai

120 Bone metastases are incurable.

121 Prostate cancer bone metastases are primarily osteoblastic, but the sour

122 Osteoblastic bone metastases are the most common metastases produced

123 Bone metastases are the most common skeletal complicatio

124 Prostate cancer (PCa)bone metastases are unique in that majority of them indu

125 Conclusion: Bone metastases as assessed with (68)Ga-PSMA-11 PET/CT a

126 n has produced unprecedented improvements in bone metastases as detected by (99m)Tc-MDP bone scans.

127 to reduced blood vessel density in brain and bone metastases as well as decreased osteolytic bone les

128 he number of patients reporting no pain from bone metastases, as measured by the BPI, increased from

129 ses in volume and increases in median ADC of bone metastases assessed with whole-body DWI can potenti

130 with pain at sites of previously irradiated bone metastases benefit from reirradiation.

131 Iodine-positive bone metastases (BMs) are often resistant after initial

132 Zoledronic acid reduced the development of bone metastases, both as a first event (HR 0.78, 95% CI

133 ith castration-resistant prostate cancer and bone metastases but its role earlier in the natural hist

134 ld better sensitivity for liver and possibly bone metastases but not for pulmonary metastases, as com

135 tic resonance imaging of his spine confirmed bone metastases but showed no evidence of extension into

136 hypercalcemia, tumor growth, and osteolytic bone metastases, but it is not known how PTHrP is upregu

137 tracers have been shown to be able to detect bone metastases, but more research regarding their use f

138 proportion of breast cancer patients develop bone metastases, but the mechanisms regulating tumor cel

139 The enhancement of lung and bone metastases by CCL2 was associated with increased ma

140 ents, including 30 with and 30 without known bone metastases by conventional imaging, underwent Na(18

141 ene, which was confirmed in larger series of bone metastases by fluorescence in situ hybridisation (F

142 TGF-beta derived from bone fuels melanoma bone metastases by inducing tumor secretion of prometast

143 apoptosis, whereas the PDZ1 domain promotes bone metastases by stimulating podosome nucleation, moti

144 Bone metastases can cause pain and greatly elevate the r

145 n 12 mo (P = 0.003), suggesting that earlier bone metastases cause an increased recruitment of alpha(

146 Breast cancer (BCa) bone metastases cause osteolytic bone lesions, which res

147 tion prevented the development of osteolytic bone metastases compared with vehicle.

148 ain response was assessed with International Bone Metastases Consensus Endpoint Definitions.

149 and normal bone, (18)F-fluoride transport in bone metastases, correlation with progression-free survi

150 ouraging activity in patients with mCRPC and bone metastases; definitive phase III trials of this age

151 patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4

152 me points (baseline and week 12) and who had bone metastases detectable at baseline.

153 , 10-20, and >20 ng/mL) and the incidence of bone metastases detected by total-body (68)Ga-prostate-s

154 detected 97 metastatic lesions, and 44 of 56 bone metastases detected on CTT1057 PET (78.5%) were als

155 (18)F-FES PET was especially sensitive for bone metastases, detecting 341 bone lesions, compared wi

156 cells may lie dormant for many years before bone metastases develop.

157 PET/CT outperformed conventional imaging for bone metastases, distant lymph nodes, and liver metastas

158 Among patients with bone metastases due to breast cancer, prostate cancer, o

159 tions of (223)Ra-dichloride in patients with bone metastases due to castration-refractory prostate ca

160 45 patients with castration-resistant PC and bone metastases during (223)Ra-dichloride were retrospec

161 Na(18)F PET/CT detects more bone metastases earlier than (99m)Tc-BS and enhances det

162 ith castration-sensitive prostate cancer and bone metastases, early treatment with zoledronic acid wa

163 tic castration-resistant prostate cancer and bone metastases, Eastern Cooperative Oncology Group perf

164 s (SRE) in patients with advanced cancer and bone metastases (excluding breast and prostate) or myelo

165 ients responding to reirradiation of painful bone metastases experience superior QOL scores and less

166 e palliative radiotherapy interventions, and bone metastases fractionation has become the first radio

167 Bone metastases frequently cause skeletal events in pati

168 performed on eleven patients diagnosed with bone metastases from breast and prostate cancers before

169 ting tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard

170 randomized 416 women (>/=18 years old) with bone metastases from breast cancer who previously receiv

171 for therapeutic monitoring in patients with bone metastases from breast cancer.

172 stemic anticancer therapy (SACT) response in bone metastases from metastatic breast cancer (MBC).

173 been shown to palliate pain in patients with bone metastases from multiple primary origin sites, data

174 rown in mouse bone xenografts, as well as in bone metastases from patients with breast cancer as comp

175 tial for outcome prediction in patients with bone metastases from PC.

176 highly sensitive method in the evaluation of bone metastases from prostate cancer, but it has problem

177 ic treatment approaches to prevent and treat bone metastases from solid tumours as well as myeloma bo

178 essed in human prostate cancer specimens and bone metastases from xenograft mouse models of human pro

179 ke (TLF10) and total volume of fluoride avid bone metastases (FTV10).

180 of SK3 and Orai1 in primary human tumors and bone metastases further emphasized the clinical relevanc

181 Changes in (18)F-fluoride incorporation in bone metastases had borderline correlation with PFS by S

182 >/=2 points using the Brief Pain Inventory) bone metastases, had received previous radiation therapy

183 errantly expressed in PCa cells derived from bone metastases, has been shown to play a role in the me

184 quality of life (QOL) after radiotherapy of bone metastases have small sample sizes and do not use s

185 r performance status, a higher prevalence of bone metastases, higher PSA levels, lower hemoglobin lev

186 f lesions in 13 patients and the location of bone metastases in 1 patient.

187 servers agreed on the number and location of bone metastases in 205 (93.6%) patients.

188 Lymph nodes were detected in 23 patients and bone metastases in 5 on (68)Ga-PSMA-11 PET/MRI.

189 was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%).

190 increased prometastatic gene expression and bone metastases in a mouse prostate cancer model.

191 incremental value in response assessment of bone metastases in breast cancer compared with SUV(max)

192 tter way to assess the treatment response of bone metastases in clinical trials.

193 bisphosphonates can reduce the incidence of bone metastases in early breast cancer.

194 gulation of the EGFR signaling axis enhances bone metastases in many solid cancers.

195 ight modulate the development of symptomatic bone metastases in men with prostate cancer.

196 s attenuates their ability to form brain and bone metastases in mice, independently of effects on tum

197 rated specific localization to breast cancer bone metastases in mice.

198 ent on (18)F-NaF PET/CT for the detection of bone metastases in patients with PCa was very high among

199 m fluoride (NaF) PET/CT for the detection of bone metastases in patients with prostate cancer (PCa).

200 vide greater specificity in the detection of bone metastases in patients with prostate cancer.

201 ted primary tumors as well as lymph node and bone metastases in patients with sarcoma.

202 luable biomarker to assess the occurrence of bone metastases in RCC patients.

203 s should be offered re-treatment for painful bone metastases in the hope of reducing pain severity as

204 ultures and suppresses their ability to form bone metastases in vivo.

205 is particularly true of pain associated with bone metastases, in part because existing analgesic drug

206 ession of TGF-beta target genes that enhance bone metastases, including PTHrP, CTGF, CXCR4, and IL11.

207 aracrine factors modulate various aspects of bone metastases, including tumour proliferation, skeleta

208 on-resistant prostate cancer and symptomatic bone metastases, irrespective of previous docetaxel use.

209 castration-refractory prostate cancer (CRPC) bone metastases is a common event.

210 Biopsy of bone metastases is challenging; hence, sampling circulat

211 Treatment for bone metastases is not curative, therefore new adjuvant

212 bisphosphonates and the apatite structure of bone metastases is strong.

213 c activity, the relation between them in PCa bone metastases is unknown.

214 as osteosarcoma and prostate cancer-induced bone metastases, its regulation of breast cancer bone me

215 rge proportion of solid tumor metastases are bone metastases, known to usurp HSC homing pathways to e

216 Coinjection of patient-derived CAFs from bone metastases led to de novo HTR tumors, which was rev

217 a patient level using a 3-category scale (no bone metastases [M0], equivocal for bone metastases, and

218 N1/M1a) were detected in 31.4% (217/691) and bone metastases (M1b) in 16.8% (116/691).

219 ta (TGF-beta) in the myeloid lineage, in BCa bone metastases, MDA-MB-231 BCa cells were intra-tibiall

220 emotherapy itself induces chemoresistance of bone metastases, mediated by osteoblast Jagged1-induced

221 ment of Cancer Quality of Life Questionnaire Bone Metastases Module (QLQ-BM22) and the European Organ

222 tionation schedules in patients with painful bone metastases needing repeat radiation therapy.

223 nt prostate cancer, at least two symptomatic bone metastases, no known visceral metastases, and who w

224 samples and regions of interest placed over bone metastases, normal vertebrae, and cardiac blood poo

225 Bone metastases occur in approximately 70% of metastatic

226 Bone metastases occurred most frequently in restaging M1

227 e evaluated the ability of GM-CSF to promote bone metastases of breast cancer or prostate cancer in a

228 known or shelved drugs for brain, lung, and bone metastases of breast cancer with the hypothesis tha

229 significantly contribute to osteoporosis and bone metastases of cancer.

230 t3 is active in 77% of lymph node and 67% of bone metastases of clinical human prostate cancers.

231 e report that HER2 expression is elevated in bone metastases of prostate cancer independently of gene

232 ring 20 years of follow-up, 44 men developed bone metastases or died of cancer.

233 y 660 men were anticipated to have developed bone metastases or died.

234 Eight patients with bone metastases or equivocal results on NaF PET/CT exhib

235 s of RCC patients with regard to visceral or bone metastases or localized disease (p = 0.22).

236 secondary causes of high bone turnover (eg, bone metastases or multiple myeloma).

237 lity of Na(18)F PET/CT to detect and monitor bone metastases over time and its correlation with clini

238 on-resistant prostate cancer and symptomatic bone metastases, overall survival was significantly long

239 tumors within the dynamic field of view) in bone metastases (P = 0.0002), with a significant differe

240 ses [M0], equivocal for bone metastases, and bone metastases present [M1]) and on a dichotomous scale

241 e in the prostatectomy bed as well as LN and bone metastases, rating their diagnostic confidence with

242 ution of CD8(+) T cells in the regulation of bone metastases regardless of OC status, thus including

243 atients, beta3 was significantly elevated on bone metastases relative to primary tumors from the same

244 metastases, its regulation of breast cancer bone metastases remains unknown.

245 n different mouse models of human osteolytic bone metastases-representing breast, lung and prostate c

246 In patients with painful bone metastases requiring repeat radiation therapy, trea

247 h factor beta (TGFbeta) signaling pathway in bone metastases, sequentially over time in the same anim

248 A single 8-Gy radiotherapy dose for bone metastases should be offered to all patients, even

249 ents with breast cancer who have evidence of bone metastases should be treated with BMAs.

250 at days 10 and 42 after radiotherapy with a bone metastases-specific QOL tool.

251 e metastatic sites and those with hepatic or bone metastases, specifically.

252 atients and in three individual cohorts with bone metastases, strengthening the clinical relevance of

253 cause PTHrP contributes to hypercalcemia and bone metastases, switching of G-protein usage by the CaR

254 ry significantly more tumorigenic in forming bone metastases than fast-growing cells (55 vs. 15%) and

255 nd symptom control (including pain relief in bone metastases) than those treated with either incomple

256 a Notch3-MMP-3 axis in human prostate cancer bone metastases that contributes to osteoblastic lesion

257 tients with well-differentiated NETs who had bone metastases that were positive on [(111)In-DTPA(0)]o

258 n advanced disease, especially for assessing bone metastases, the prevalent form of metastases in thi

259 In mice with established bone metastases, the size of osteolytic lesions was sign

260 In about half of matched bone metastases there is significant dystroglycan re-exp

261 quences for the detection of probable spinal bone metastases, thereby providing an opportunity to red

262 ith castration-resistant prostate cancer and bone metastases; therefore, single-agent docetaxel shoul

263 vasive DFS (IDFS), overall survival, time to bone metastases, time to distant recurrence, and subgrou

264 e, is commonly administered to patients with bone metastases to reduce the risk of skeletal-related e

265 ging biomarker for assessing the response of bone metastases to therapy.

266 hted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic

267 Furthermore, mice with established bone metastases treated with halofuginone had significan

268 PS of 1 or 2, dyspnea, weight loss, liver or bone metastases, unmarried, presence of adrenal metastas

269 By analysing prostate cancer bone metastases using high density microarrays, we found

270 atment allocation used minimization factors: bone metastases; visceral metastases; investigational si

271 ivity concentrations, and K(i) in individual bone metastases was calculated using a previously valida

272 A final diagnosis of bone metastases was made for 211 of 219 patients.

273 gnosis of local recurrence and pelvic LN and bone metastases was met in 87, 70, and 95 patients, resp

274 ocumented local recurrence and pelvic LN and bone metastases was present in 61 of 87 (70.1%), 50 of 7

275 hanges associated with breast cancer-induced bone metastases, we identified cathepsin G, cathepsin K,

276 gnosis of local recurrence and pelvic LN and bone metastases were 0.909 versus 0.761 (P = 0.0079), 0.

277 eas those of PET/CT for detecting body LN or bone metastases were 92.3% (72/78), 100% (18/18), and 93

278 ith chemotherapy-naive mCRPC and evidence of bone metastases were assigned (2:1) to receive tasquinim

279 Bone metastases were confirmed in 16 patients and exclud

280 gnal intensity on DWI images in keeping with bone metastases were delineated to derive total diffusio

281 Bone metastases were identified and delineated on whole-

282 d 2 patients did not undergo surgery because bone metastases were identified preoperatively on (18)F-

283 +/- 11.8) performed for suspected vertebral bone metastases were included in this retrospective, ins

284 docrine treatment for de novo or progressive bone metastases were included.

285 Bone metastases were present in 70% of patients, and vis

286 Participants referred for radiotherapy for bone metastases were required to have a pain score at th

287 d SK3-dependent Ca(2+) entry, migration, and bone metastases were subsequently impaired.

288 age >/= 18 years, had radiologically proven bone metastases, were scheduled to receive radiotherapy,

289 ny disease and (223)RaCl2 for the therapy of bone metastases-were recently shown to be superior to st

290 rylation is significantly increased in human bone metastases when compared with normal tissues, prima

291 may be achievable in prostate cancer and in bone metastases, whereas disadvantages exist in lung nod

292 up-regulated in primary prostate cancers and bone metastases, whereas PDGF B, a classic ligand for be

293 The endothelin pathway has a role in bone metastases, which are characteristic of advanced pr

294 ith castration-sensitive prostate cancer and bone metastases whose androgen-deprivation therapy was i

295 agement of patients with prostate cancer and bone metastases with a particular emphasis on recent adv

296 -223), an alpha emitter, selectively targets bone metastases with alpha particles.

297 eate treatment response of dasatinib in CRPC bone metastases with borderline correlation with PFS.

298 dichloride (radium-223) selectively targets bone metastases with high-energy, short-range alpha-part

299 e T1-weighted sequences for the detection of bone metastases, with the hypothesis that diagnostic per

300 tient population with a higher prevalence of bone metastases would have to be studied to demonstrate